Breast cancer cells' self-sacrificial behavior uncovered as potential cause of relapse
For patients with early-stage breast cancer, there is a 7% to 11% chance of relapse within five years after receiving initial treatment,...
Major Vaccine Breakthrough Could Spell Hope For Treating Aggressive Breast Cancer
The results of a small clinical trial of a vaccine for an aggressive form of breast cancer have been presented at a conference, and the...
AI may spare breast cancer patients unnecessary treatments
A new artificial intelligence (AI) tool may make it possible to spare breast cancer patients unnecessary chemotherapy treatments by using...
US FDA approves AstraZeneca's breast cancer drug combination
The U.S. Food and Drug Administration on Thursday approved AstraZeneca's (AZN.L) Truqap in combination with an older drug, providing...
With breast cancer risks, where you live matters, researchers find
Inadequate health care access, unhealthy diets and not enough exercise are all well-known risk factors for the number one cause of...
New robot could help diagnose breast cancer early
A device has been created that could carry out clinical breast examinations (CBE). The manipulator, designed by a team at the University...
AstraZeneca, Daiichi hit first goal in pivotal breast cancer ADC trial
AstraZeneca and Daiichi Sankyo are coming for Gilead Sciences' breast cancer business. The partners plan to file for approval of...
AI shows major promise in breast cancer detection, new studies suggest
Researchers experimenting with artificial intelligence have found that these tools seem to reliably detect breast cancer, while also...
Trodelvy Improves Survival for Patients with HR2+/HER- Breast Cancer
Treatment with Trodelvy (sacituzumab govitecan) significantly improved survival among some patients with breast cancer, according to the...
UPMC, Pitt to test 'revolutionary' breast cancer vaccine
UPMC and University of Pittsburgh researchers will test a vaccine to prevent breast cancer in what they say is a revolutionary step in...
